Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy.
Zila N, Eichhoff OM, Steiner I, Mohr T, Bileck A, Cheng PF, Leitner A, Gillet L, Sajic T, Goetze S, Friedrich B, Bortel P, Strobl J, Reitermaier R, Hogan SA, Martínez Gómez JM, Staeger R, Tuchmann F, Peters S, Stary G, Kuttke M, Elbe-Bürger A, Hoeller C, Kunstfeld R, Weninger W, Wollscheid B, Dummer R, French LE, Gerner C, Aebersold R, Levesque MP, Paulitschke V. Zila N, et al. Among authors: paulitschke v. Clin Cancer Res. 2024 Jan 5;30(1):159-175. doi: 10.1158/1078-0432.CCR-23-0562. Clin Cancer Res. 2024. PMID: 37861398
Erlotinib and bevacizumab have synergistic activity against melanoma.
Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C. Schicher N, et al. Among authors: paulitschke v. Clin Cancer Res. 2009 May 15;15(10):3495-502. doi: 10.1158/1078-0432.CCR-08-2407. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447871
Curing advanced melanoma by 2025.
Dummer R, Goldinger SM, Paulitschke V, Levesque MP. Dummer R, et al. Among authors: paulitschke v. Curr Opin Oncol. 2015 Mar;27(2):125-7. doi: 10.1097/CCO.0000000000000168. Curr Opin Oncol. 2015. PMID: 25646843 Free article. Review.
Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, Stephan J, Mangana J, Kunstfeld R, Pehamberger H, Aebersold R, Dummer R, Levesque MP. Paulitschke V, et al. EMBO J. 2019 Aug 1;38(15):e95874. doi: 10.15252/embj.201695874. Epub 2019 Jun 26. EMBO J. 2019. PMID: 31267558 Free PMC article.
ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A; TuPro Consortium; Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, Levesque MP. Eichhoff OM, et al. Among authors: paulitschke v. Cancer Res. 2023 Apr 4;83(7):1128-1146. doi: 10.1158/0008-5472.CAN-22-1826. Cancer Res. 2023. PMID: 36946761
Proteome profiling of keratinocytes transforming to malignancy.
Paulitschke V, Gerner C, Hofstätter E, Mohr T, Mayer RL, Pehamberger H, Kunstfeld R. Paulitschke V, et al. Electrophoresis. 2015 Feb;36(4):564-76. doi: 10.1002/elps.201400309. Epub 2015 Jan 28. Electrophoresis. 2015. PMID: 25395074
31 results